New combo therapy aims to shrink tumors before esophageal cancer surgery
NCT ID NCT05176002
Summary
This study is testing if adding an immunotherapy drug (camrelizumab) to standard radiation helps shrink tumors before surgery for esophageal cancer. It will involve 25 patients with operable esophageal squamous cell carcinoma. The main goals are to see if this combination is safe and if it leads to a strong reduction or complete disappearance of cancer cells in the removed tumor.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for RADIOTHERAPY are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Fujian Medical University Union Hospital
Fuzhou, Fujian, 350001, China
Conditions
Explore the condition pages connected to this study.